Výsledky vyhledávání - "Philippe Giguere-Duval"

Assessment of treatment patterns and healthcare costs associated with probable Lennox–Gastaut syndrome

Autor: J. Eric Piña-Garza, Mei Sheng Duh, Jouko Isojarvi, Francis Vekeman, Vivienne Shen, Edward Tuttle, Georgia Montouris, Timothy B. Saurer, Wendy Y. Cheng, Philippe Giguere-Duval

Publikováno v: Epilepsy & Behavior. 73:46-50

Lennox-Gastaut syndrome (LGS) is a chronic and severe form of epilepsy characterized by intractable seizures, cognitive impairment, and abnormal electroencephalogram findings with slow spike-wave complexes. It typically presents before age 8, but sym

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebe819c1966c1b0d94a576eec40252cf
https://doi.org/10.1016/j.yebeh.2017.05.021

Zobrazit plný text záznamu

Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology

Autor: Jesus Eric Piña-Garza, Philippe Giguere-Duval, Mei Sheng Duh, Timothy B. Saurer, Joseph Damron, Jouko Isojarvi, Francis Vekeman, Georgia Montouris, Edward Tuttle, Wendy Y. Cheng, Vivienne Shen, Arman Oganisian

Publikováno v: Current medical research and opinion. 35(8)

Objective: Describe the development of a claims-based classifier utilizing machine learning to identify patients with probable Lennox–Gastaut syndrome (LGS) from six state Medicaid programs.Methods...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e832e1d49e45a0cfd1f0a77400cc5e56
https://pubmed.ncbi.nlm.nih.gov/30870597

Zobrazit plný text záznamu

Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis

Autor: Daniel J. DeAngelo, Philippe Giguere-Duval, Amy Styles, Annie Guerin, Lei Chen, Eric Q. Wu

Publikováno v: Clinical lymphoma, myelomaleukemia. 14(3)

Introduction In this study, cytogenetic response rate after timely switching to a second-generation tyrosine kinase inhibitor (TKI) was evaluated among patients with CML-CP, after failure to achieve CCyR 1 year after imatinib initiation. Patients and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db95d26ebb95238c0375fb376f7fa28
https://pubmed.ncbi.nlm.nih.gov/24393622

Zobrazit plný text záznamu

Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab

Autor: Eduardo Santos, Deepa Lalla, Melissa Brammer, Eric Q. Wu, Geneviève Gauthier, Annie Guerin, Philippe Giguere-Duval

Publikováno v: Journal of Clinical Oncology. 31:e11603-e11603

e11603 Background: It is unknown if quality of care received by patients (pts) with BC is impacted by the location at which care is received. Using a sample of pts with HER2+ BC receiving adjuvant trastuzumab (T), we compared T treatment patterns bet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e0e9c9e254cf300480456cd158f1341
https://doi.org/10.1200/jco.2013.31.15_suppl.e11603

Zobrazit plný text záznamu

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis

Autor: Clemence Aberki, Daniel J. DeAngelo, Annie Guerin, Eric Q. Wu, Philippe Giguere-Duval, Lei Chen, Amy Styles

Publikováno v: Blood. 120:2792-2792

Abstract 2792 Background: The National Comprehensive Cancer Network (NCCN) guidelines (version 1.2013) recommend that patients with chronic myelogenous leukemia in chronic phase (CML-CP) should be tested for cytogenetic response 12 months following i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c297d2dc1cebba360c9974d942e3182b
https://doi.org/10.1182/blood.v120.21.2792.2792

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání